Royalty Pharma plc

NasdaqGS:RPRX 주식 리포트

시가총액: US$30.7b

Royalty Pharma 향후 성장

Future 기준 점검 5/6

Royalty Pharma (는) 각각 연간 38.8% 및 15.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 13.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 27.3% 로 예상됩니다.

핵심 정보

38.8%

이익 성장률

13.48%

EPS 성장률

Pharmaceuticals 이익 성장11.9%
매출 성장률15.6%
향후 자기자본이익률27.34%
애널리스트 커버리지

Low

마지막 업데이트08 May 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • May 02

RPRX: Royalty Deals And Buybacks Will Shape Balanced Forward Outlook

Analysts have raised their blended price target on Royalty Pharma by several dollars to around the mid $40s, citing refined models that factor in slightly higher projected revenue growth, modestly lower profit margins, and continued benefits from recent royalty and financing deals such as the $250m Zymeworks agreement. Analyst Commentary Recent research on Royalty Pharma centers on how the updated price targets line up with the company’s deal pipeline, especially the $250m Zymeworks transaction.
내러티브 업데이트 • Apr 17

RPRX: Diversified Royalty Portfolio And Recent Deals Will Support Future Upside

Analysts have nudged their price targets for Royalty Pharma modestly higher, with the average fair value estimate moving from about $59.28 to $60.61. They point to the company's diversified royalty portfolio, favorable deal terms such as the $250m Zymeworks financing, and the broader growth of the biopharma royalty market.
내러티브 업데이트 • Apr 03

RPRX: Royalty Deals And Dividend Policy Will Shape Balanced Forward Outlook

Analysts have raised the fair value estimate for Royalty Pharma to $46.00 from $40.86, citing updated models that reflect perceived strengths in its biopharma royalty exposure, portfolio diversification, and recent deal activity. Analyst Commentary Recent Street research around Royalty Pharma highlights both constructive and cautious views, giving you a mixed picture of how professionals are thinking about the stock.
내러티브 업데이트 • Mar 19

RPRX: Royalty Deals And Buybacks Will Support Future Upside

Analysts have lifted their price target on Royalty Pharma to $51.56 from $51.00, citing updated Street views on its biopharma royalty exposure and recent deal activity as key supports for the revised fair value estimate. Analyst Commentary Recent Street commentary on Royalty Pharma highlights a mix of optimism around its royalty portfolio and business model, alongside some areas where investors may want to stay cautious on execution and deal risk.
내러티브 업데이트 • Mar 05

RPRX: Royalty Platform And Portfolio Diversification Will Drive Future Upside Potential

Analysts have nudged their targets higher on Royalty Pharma, with the consensus fair value estimate moving from $56.00 to about $59.28. They cite expectations for the company to benefit from growth in the biopharma royalty market, differentiation from competitors, and a more diversified portfolio.
내러티브 업데이트 • Feb 19

RPRX: Higher P/E Expectations And Buybacks Will Support Future Upside

Analysts have lifted their average price target on Royalty Pharma from about $46 to roughly $51, citing updated assumptions for fair value, discount rate, growth, margins, and a higher future P/E multiple as key drivers behind the move. Analyst Commentary Recent research coverage on Royalty Pharma has centered on refreshed models for fair value and updated assumptions around discount rates, growth, margins, and future P/E multiples.
Seeking Alpha • Feb 12

Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View

Summary Royalty Pharma delivered robust 2025 results, with Q4 receipts up 17% to $856 million and full-year portfolio receipts at $3.25 billion. The company deployed $2.6 billion into 9 new royalties and repurchased $1.2 billion in shares, reflecting disciplined capital allocation and shareholder focus. Even factoring in patent expiries and a more conservative growth outlook, valuation remains attractive, supported by sector momentum and sustained capital returns. Read the full article on Seeking Alpha
분석 기사 • Feb 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235

Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...
내러티브 업데이트 • Feb 05

RPRX: Pending XenoTherapeutics Deal And Dividend Increase Will Shape Near-Term Returns

Analysts have raised their price targets on Royalty Pharma by about $2 to an updated fair value of US$40.86, citing slightly higher long term revenue growth assumptions, a modestly higher future P/E multiple, and largely unchanged discount rate and profit margin inputs. Analyst Commentary Recent research on Royalty Pharma has been mixed, with some firms updating ratings and price targets around the company’s agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.
분석 기사 • Jan 22

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...
내러티브 업데이트 • Jan 21

RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside

Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.
내러티브 업데이트 • Jan 07

RPRX: Agreed XenoTherapeutics Deal Will Highlight Upside In Royalty Portfolio Earnings Power

Analysts have nudged their fair value target for Royalty Pharma up to US$56.00 from US$55.00. This reflects updated assumptions on slower revenue growth, higher margins and a lower future P/E, while also factoring in the recent downgrade to Hold following the agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.
내러티브 업데이트 • Dec 15

RPRX Pending XenoTherapeutics Deal Will Anchor Shares Near Buyout Price

Analysts have nudged their price target on Royalty Pharma up by $1, to $38. This reflects modestly stronger revenue growth assumptions, offset by a slightly higher discount rate and lower projected profit margins, and incorporates the limited upside they see given the pending acquisition by XenoTherapeutics.
내러티브 업데이트 • Dec 01

RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion

Analysts have revised Royalty Pharma's price target slightly upward from $45.54 to $45.98. They note that the pending acquisition by XenoTherapeutics has reduced uncertainty around the company’s valuation.
내러티브 업데이트 • Nov 17

RPRX: Share Buybacks And Acquisition Will Drive Outperformance After Downgrade

Analysts have raised Royalty Pharma's price target from $44.10 to $45.54, reflecting updated expectations for revenue growth. However, profit margins are anticipated to decrease following recent acquisition developments.
내러티브 업데이트 • Nov 02

RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside

Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.
내러티브 업데이트 • Sep 04

Emerging Therapies And Licensing Will Expand Royalty Opportunities

Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.
분석 기사 • Jul 06

Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...
분석 기사 • May 31

Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Seeking Alpha • Feb 13

Royalty Pharma: Delivering Growth With A Positive Story Ahead

Summary Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend). Read the full article on Seeking Alpha
Seeking Alpha • Jan 15

Royalty Pharma: Key Strategic Updates To Be Priced In

Summary Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating. Read the full article on Seeking Alpha
Seeking Alpha • Nov 09

Royalty Pharma: Massive Opportunity Ahead

Summary Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With a compelling valuation, a $1 billion buyback, and a supportive pipeline, Royalty Pharma is a strong buy. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NasdaqGS:RPRX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20283,9532,7123,5843,3483
12/31/20273,6592,1993,3223,0075
12/31/20263,4301,5973,1952,8535
3/31/20262,4418264632,612N/A
12/31/20252,3787717922,490N/A
9/30/20252,3507669452,405N/A
6/30/20252,3051,0227132,406N/A
3/31/20252,2641,0942802,700N/A
12/31/20242,2648592632,769N/A
9/30/20242,2661,145-2122,799N/A
6/30/20242,2386734012,669N/A
3/31/20242,2397991,0192,619N/A
12/31/20232,3551,1358722,988N/A
9/30/20232,3241841,4222,785N/A
6/30/20232,3612555222,750N/A
3/31/20232,3593323742,718N/A
12/31/20222,237434022,144N/A
9/30/20222,2475074012,064N/A
6/30/20222,2594663121,995N/A
3/31/20222,2786022631,952N/A
12/31/20212,289620-1742,018N/A
9/30/20212,286783-7322,093N/A
6/30/20212,239972-1592,132N/A
3/31/20212,195493-4962,090N/A
12/31/20202,122495-1482,035N/A
9/30/20202,0081,7451041,947N/A
6/30/20201,9341,8637931,858N/A
3/31/20201,8802,0521,0931,705N/A
12/31/20191,8142,349N/A1,667N/A
12/31/20181,7951,378N/A1,618N/A
12/31/20171,5981,210N/A1,418N/A

애널리스트 향후 성장 전망

수입 대 저축률: RPRX 의 연간 예상 수익 증가율(38.8%)이 saving rate(3.5%)보다 높습니다.

수익 vs 시장: RPRX 의 연간 수익(38.8%)이 US 시장(16.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: RPRX 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: RPRX 의 수익(연간 15.6%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: RPRX 의 수익(연간 15.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: RPRX의 자본 수익률은 3년 후 27.3%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/15 23:14
종가2026/05/15 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Royalty Pharma plc는 14명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Jason Matthew GerberryBofA Global Research
Geoffrey MeachamCitigroup Inc
Prem ChulakiCrispIdea